

Ophthalmic Pilocarpine Quantity Limit Program Summary

Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx.

POLICY REVIEW CYCLE

Effective DateDate of Origin
10/1/2023
7/1/2022

FDA APPROVED INDICATIONS AND DOSAGE

See package insert for FDA prescribing information: https://dailymed.nlm.nih.gov/dailymed/index.cfm

POLICY AGENT SUMMARY OUANTITY LIMIT

Target Brand Agent Name(s)	_	Strengt h	QL Amount	Dose Form	Day Supply		Addtl QL Info	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
Vuity	Pilocarpine HCl Ophth Soln	1.25 %	5	mL	30	DAYS			

CLIENT SUMMARY - QUANTITY LIMITS

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Vuity	Pilocarpine HCl Ophth Soln		FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx

QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
QL	Quantity limit for the Target Agent(s) will be approved when ONE of the following is met:
	 The requested quantity (dose) does NOT exceed the program quantity limit OR The requested quantity (dose) is greater than the program quantity limit AND BOTH of the following: A. The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication AND B. Information has been provided to support therapy with a higher dose for the requested indication
	Length of Approval: 12 months